DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

by · The Cerbat Gem

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $12.3333.

A number of research analysts have recently issued reports on DMAC shares. Wall Street Zen cut shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. TD Cowen started coverage on DiaMedica Therapeutics in a research report on Thursday, October 30th. They issued a “buy” rating for the company. Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th. Cowen initiated coverage on DiaMedica Therapeutics in a research note on Thursday, October 30th. They issued a “buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, October 8th.

Check Out Our Latest Stock Report on DMAC

Insider Activity at DiaMedica Therapeutics

In related news, major shareholder Jan Stahlberg purchased 73,099 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was acquired at an average price of $8.57 per share, with a total value of $626,458.43. Following the completion of the acquisition, the insider directly owned 8,825,742 shares in the company, valued at approximately $75,636,608.94. This trade represents a 0.84% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased 1,061,277 shares of company stock worth $7,632,627 over the last quarter. 7.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in DMAC. Royal Bank of Canada lifted its stake in shares of DiaMedica Therapeutics by 46,879.1% during the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after acquiring an additional 154,701 shares during the period. Goldman Sachs Group Inc. lifted its position in DiaMedica Therapeutics by 76.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock valued at $462,000 after purchasing an additional 52,854 shares during the period. Jane Street Group LLC boosted its stake in shares of DiaMedica Therapeutics by 138.5% in the 1st quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock valued at $382,000 after purchasing an additional 58,457 shares during the last quarter. Perigon Wealth Management LLC acquired a new stake in shares of DiaMedica Therapeutics during the 2nd quarter worth approximately $207,000. Finally, World Investment Advisors grew its position in shares of DiaMedica Therapeutics by 24.7% during the 2nd quarter. World Investment Advisors now owns 31,975 shares of the company’s stock worth $125,000 after buying an additional 6,325 shares during the period. 10.12% of the stock is owned by institutional investors and hedge funds.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ:DMAC opened at $7.57 on Tuesday. The company’s fifty day moving average is $8.11 and its 200-day moving average is $6.63. DiaMedica Therapeutics has a 52 week low of $3.19 and a 52 week high of $10.42. The company has a market capitalization of $394.22 million, a PE ratio of -10.66 and a beta of 1.15.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, analysts forecast that DiaMedica Therapeutics will post -0.59 EPS for the current year.

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.

See Also